20 June 2013
Keywords: celgene, revlimid, gets, nod, adec, swiss, unit
Article | 19 November 2007
The Swiss unit of US drugmaker Celgene says that its oral cancer drug Revlimid (lenalidomide) has received a recommendation for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 November 2007
19 June 2013
© 2013 thepharmaletter.com